Best Life Sciences Platforms and Tools Companies in San Francisco, United States

Manufacturer of a medical device for cell-based therapy. The company offers Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. It also, offers software suite for cell therapy modalities.

Funding rounds

• Jan 2026Series D$257M
• Aug 2023Series C$255M
• Apr 2021Series B$82M
• Aug 2019Series A$18M

Founders & team

Fabian GerlinghausCo-Founder & CEOOmar KurdiCo-Founder

Investors

8VC, EcoR1, Eclipse, Decheng Capital, Skyviews Life Science, Koch Disruptive Technologies

Tech stack

Apple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCloudflare Browser InsightsCookieyes

Provider of biomanufacturing hardware and software tools for research purposes. They have developed the digital biomanufacturing platform by integrating automated bioreactors, robotic sample handling, and cloud data monitoring. It offers services such as strain screening, media optimization, and process development.

Funding rounds

• Dec 2025Series C—
• Oct 2021Series B$80M
• Mar 2020Series A$21.6M
• Sep 2019Grant (prize money)$750K

Founders & team

Chris WilliamsCEODarcy BirseChief Executive Officer (interim)

Investors

Cultivian Sandbox, E14 Fund, Y Combinator, Verily, The Production Board, S32

Tech stack

CloudflareCloudflare Bot ManagementCore-JsFont AwesomeGoogle AdsGoogle Ads Conversion Tracking

Provider of a single-cell multi-omics platform for genotypic and phenotypic analysis. The company's proprietary Tapestri platform enables the simultaneous detection of analytes, including SNVs, CNVs, and proteins for the precise treatment of cancer. Also, it offers DNA & protein panels, and Pharma Assay Development (PAD) Services.

Funding rounds

• Aug 2025Series C—
• Aug 2020Series C$70M
• Oct 2019Grant (prize money)$2M
• Sep 2019Grant (prize money)$1.8M

Founders & team

Adam SciambiCo-Founder & Chief Technology OfficerCharlie SilverCo-FounderBrian KimCEO

Investors

Agilent, Cota Capital, Mayfield, Lam Research Capital, LabCorp, NHGRI

Tech stack

Adobe Audience ManagerApple Icloud MailBamboohrBootstrapCloudflareCloudflare Bot Management

Developer of RNA foundation models for precision medicine research applications. The company builds models combining isoform, mutation, and expression signals from RNA. These models aim to improve patient stratification and boost diagnostic accuracy. Applications include patient stratification, enhanced diagnostics, target discovery, therapeutic design, and biosecurity monitoring. The company focuses on fine-tuning models for specific needs.

Funding rounds

• May 2026Seed$7.2M

Founders & team

Jonathan HsuCo-Founder & CEORuian ShiCo-FounderPhilip FradkinCo-Founder

Investors

Define Ventures, Leonis Capital, Nova Threshold, Ripple Ventures, SignalFire, Y Combinator

Provider of AI-native protein characterization platform for biopharma. The platform uses AI agents to perform protein analysis, peptide mapping, and detection of modifications like glycosylation for drug development. It enables scientists to steer AI workflows for high-throughput characterization, integrating mass spectrometry data and resolving drug complexity. The solution addresses bottlenecks in biopharmaceutical preparation by providing scalable characterization to match AI-driven drug discovery pace.

Funding rounds

• Apr 2026Seed$4.8M
• Jan 2026Seed$500K

Founders & team

Vishnu TejusCo-Founder & CTODavid RobertsCo-Founder & CEOAndrew RCo-Founder & COO

Investors

Y Combinator, Initialized Capital, Civilization Ventures

Tech stack

CloudflareCloudflare Bot ManagementCloudflare Browser InsightsElement UiHammer.JsHsts

Provider of diagnostic solutions for systemic infections. Its proprietary technology, based on research from Stanford University, measures gene expression patterns related to the immune system to diagnose sepsis. It provides products such as InSep for acute infection and sepsis tests, ViraBac for acute infection tests, SARC-CoV-2 swabs, etc.

Funding rounds

• Sep 2024Series E$57M
• Jul 2023Grant (prize money)$299.8K
• Nov 2021Grant (prize money)$12.1M
• Nov 2021Grant (prize money)$1.7M

Founders & team

Jonathan RomanowskyCo-Founder and Chief Business Officer

Investors

GSVP, Khosla Ventures, Think.Health, Northpond Ventures, StartX, DARPA

Tech stack

BootstrapBricksCloudflareCloudflare Bot ManagementContact Form 7Core-Js

Developer of therapeutics to treat multiple diseases. The company has developed a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms used for the treatment of cancer, pain, anti-infectives, and anti-viral and immunological diseases. The product pipeline inlcude NKTR-358 for autoimmune diseases, Bempegaldesleukin for viral diseases, and other oncology indications.

Funding rounds

• Mar 2024Post IPO$30M
• Mar 2019Post IPO—
• Apr 2018Post IPO$850M
• Aug 2013Post IPO$25M

Founders & team

Rob CChairman (1999-present)

Investors

AstraZeneca, New Enterprise Associates, BB Biotech, Deerfield, ONSET Ventures

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services

Developer of cell culture analysis device for cancer research. The platform technology Avatar mimics in vivo physiological conditions for reproducible and more accurate in vitro tests. It allows for the preferential isolation and expansion of circulating tumor cells in the patient's blood. The company also provides cell-binding substrates and culture media to use in conjunction with its platform. The company has developed a cell analysis tool which is AI enables and assists with real-time analysis of cell health for identifying cell kinetics, targets, and other immunotherapy research.

Provider of animal microbiome based diagnostics services for pet care. The company allows the customers to send the sample through an assessment kit to extract and analyze the DNA to understand the pet's gut microbiome. They send an analysis report which also includes a gut health comparison tool and highlights any abnormal signs in the data. Their scientists can also talk to the pet's veterinarian about the necessary treatment options.

Funding rounds

• Aug 2024Series B$15.5M
• May 2021Series A$8.6M
• May 2021Conventional Debt—
• Feb 2020Seed$1.5M

Founders & team

Holly GanzCo-Founder & CEOCarlton OsborneChief Executive Officer

Investors

IndieBio, Cargill, SOSV, Moai Capital, Michelson Found Animals, Digitalis Ventures

Tech stack

AngularApache Http ServerApple Icloud MailApple PayBold BundlesBold Commerce

Developer of AI to predict missing patient data modalities. It offers solutions for predicting biological modalities from existing patient data. The AI helps rescue incomplete cohorts by predicting missing modalities. It also helps skip expensive assays by predicting proteomics or transcriptomics. The AI unlocks rare disease cohorts by filling in missing modalities. It imputes unmeasured markers across entire cohorts.

Funding rounds

• Jan 2026Seed$500K

Founders & team

Oded FalikCo-Founder & CTOYue DaiCo-Founder & CEO

Investors

Y Combinator

Tech stack

CloudflareCloudflare Browser InsightsGoogle Font ApiGoogle WorkspaceHttp/3Next.Js

Developer of molecular diagnostics technology designed for point-of-care clinical use. The platform offers rapid, lab-quality molecular measurements, eliminating the need for central labs. This enables healthcare providers to streamline workflows and improve diagnostic precision. Researchers can accelerate trials, supporting timely, data-driven treatment decisions.

Funding rounds

• Jul 2025Seed$2.3M

Founders & team

Austin HallCo-Founder & CPOKavya SwaminathanCo-Founder & CEOScott FergusonCo-Founder & CSO

Investors

2048 Ventures, Boost VC, Ensemble, Draper, Spacecadet

Provider of synthetic biology platform for a wide range of applications. The company offers plug-and-play Switchback platform with both onboard oligonucleotide synthesis and gene assembly capabilities fro various applications from pharmaceuticals to agriculture to plastics, and beyond.

Funding rounds

• Jul 2024Series B$11.3M
• Oct 2021Series A$7M

Founders & team

Mary NoeCEO and Co-Founder

Investors

BioTools Innovator